- Home
- JTAI vs SABS Comparison
JTAI vs SABS Comparison
Compare JTAI & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- SABS
- Stock Information
- Founded
- JTAI 2018
- SABS 2014
- Country
- JTAI United States
- SABS United States
- Employees
- JTAI N/A
- SABS N/A
- Industry
- JTAI Blank Checks
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- JTAI Finance
- SABS Health Care
- Exchange
- JTAI Nasdaq
- SABS Nasdaq
- Market Cap
- JTAI 9.9M
- SABS 11.4M
- IPO Year
- JTAI N/A
- SABS N/A
- Fundamental
- Price
- JTAI $3.93
- SABS $1.50
- Analyst Decision
- JTAI
- SABS Strong Buy
- Analyst Count
- JTAI 0
- SABS 5
- Target Price
- JTAI N/A
- SABS $11.40
- AVG Volume (30 Days)
- JTAI 74.8K
- SABS 25.0K
- Earning Date
- JTAI 05-14-2025
- SABS 05-19-2025
- Dividend Yield
- JTAI N/A
- SABS N/A
- EPS Growth
- JTAI N/A
- SABS N/A
- EPS
- JTAI N/A
- SABS N/A
- Revenue
- JTAI $14,022,628.00
- SABS $1,322,410.00
- Revenue This Year
- JTAI $16.48
- SABS N/A
- Revenue Next Year
- JTAI $193.11
- SABS $50.00
- P/E Ratio
- JTAI N/A
- SABS N/A
- Revenue Growth
- JTAI 14.80
- SABS N/A
- 52 Week Low
- JTAI $2.30
- SABS $1.00
- 52 Week High
- JTAI $175.50
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- JTAI 44.30
- SABS 53.68
- Support Level
- JTAI $3.62
- SABS $1.30
- Resistance Level
- JTAI $4.00
- SABS $1.49
- Average True Range (ATR)
- JTAI 0.36
- SABS 0.13
- MACD
- JTAI -0.01
- SABS 0.04
- Stochastic Oscillator
- JTAI 35.59
- SABS 100.00
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.